Logo image of DR.CA

MEDICAL FACILITIES CORP (DR.CA) Stock Fundamental Analysis

Canada - Toronto Stock Exchange - TSX:DR - CA58457V5036 - Common Stock

15.48 CAD
+0.06 (+0.39%)
Last: 12/22/2025, 7:00:00 PM
Fundamental Rating

7

We assign a fundamental rating of 7 out of 10 to DR. DR was compared to 14 industry peers in the Health Care Providers & Services industry. Both the health and profitability get an excellent rating, making DR a very profitable company, without any liquidiy or solvency issues. DR is cheap, but on the other hand it scores bad on growth. With these ratings, DR could be worth investigating further for value investing!.


Dividend Valuation Growth Profitability Health

8

1. Profitability

1.1 Basic Checks

In the past year DR was profitable.
DR had a positive operating cash flow in the past year.
DR had positive earnings in 4 of the past 5 years.
Each year in the past 5 years DR had a positive operating cash flow.
DR.CA Yearly Net Income VS EBIT VS OCF VS FCFDR.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M 60M 80M

1.2 Ratios

The Return On Assets of DR (30.18%) is better than 92.86% of its industry peers.
With an excellent Return On Equity value of 94.43%, DR belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
DR has a better Return On Invested Capital (15.42%) than 92.86% of its industry peers.
DR had an Average Return On Invested Capital over the past 3 years of 16.37%. This is significantly above the industry average of 7.27%.
Industry RankSector Rank
ROA 30.18%
ROE 94.43%
ROIC 15.42%
ROA(3y)8.42%
ROA(5y)6.13%
ROE(3y)25.39%
ROE(5y)18.93%
ROIC(3y)16.37%
ROIC(5y)14.6%
DR.CA Yearly ROA, ROE, ROICDR.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40 60

1.3 Margins

DR has a better Profit Margin (31.60%) than 92.86% of its industry peers.
In the last couple of years the Profit Margin of DR has grown nicely.
Looking at the Operating Margin, with a value of 15.59%, DR belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
DR's Operating Margin has been stable in the last couple of years.
With an excellent Gross Margin value of 63.75%, DR belongs to the best of the industry, outperforming 85.71% of the companies in the same industry.
In the last couple of years the Gross Margin of DR has remained more or less at the same level.
Industry RankSector Rank
OM 15.59%
PM (TTM) 31.6%
GM 63.75%
OM growth 3Y-0.97%
OM growth 5Y-1.3%
PM growth 3Y78.64%
PM growth 5Y55.2%
GM growth 3Y-0.53%
GM growth 5Y-0.42%
DR.CA Yearly Profit, Operating, Gross MarginsDR.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40 60

7

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), DR is creating value.
DR has less shares outstanding than it did 1 year ago.
Compared to 5 years ago, DR has less shares outstanding
DR has a better debt/assets ratio than last year.
DR.CA Yearly Shares OutstandingDR.CA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
DR.CA Yearly Total Debt VS Total AssetsDR.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

Based on the Altman-Z score of 1.35, we must say that DR is in the distress zone and has some risk of bankruptcy.
DR's Altman-Z score of 1.35 is fine compared to the rest of the industry. DR outperforms 71.43% of its industry peers.
DR has a debt to FCF ratio of 2.05. This is a good value and a sign of high solvency as DR would need 2.05 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 2.05, DR belongs to the top of the industry, outperforming 92.86% of the companies in the same industry.
A Debt/Equity ratio of 1.02 is on the high side and indicates that DR has dependencies on debt financing.
With a Debt to Equity ratio value of 1.02, DR perfoms like the industry average, outperforming 57.14% of the companies in the same industry.
Although DR does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
Industry RankSector Rank
Debt/Equity 1.02
Debt/FCF 2.05
Altman-Z 1.35
ROIC/WACC1.81
WACC8.5%
DR.CA Yearly LT Debt VS Equity VS FCFDR.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.3 Liquidity

A Current Ratio of 1.79 indicates that DR should not have too much problems paying its short term obligations.
DR has a better Current ratio (1.79) than 100.00% of its industry peers.
DR has a Quick Ratio of 1.67. This is a normal value and indicates that DR is financially healthy and should not expect problems in meeting its short term obligations.
With an excellent Quick ratio value of 1.67, DR belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.79
Quick Ratio 1.67
DR.CA Yearly Current Assets VS Current LiabilitesDR.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

3

3. Growth

3.1 Past

DR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 60.81%, which is quite impressive.
Looking at the last year, DR shows a very negative growth in Revenue. The Revenue has decreased by -41.68% in the last year.
DR shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -3.59% yearly.
EPS 1Y (TTM)60.81%
EPS 3Y10.86%
EPS 5Y0%
EPS Q2Q%-23.33%
Revenue 1Y (TTM)-41.68%
Revenue growth 3Y-5.96%
Revenue growth 5Y-3.59%
Sales Q2Q%-20.29%

3.2 Future

DR is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 10.76% yearly.
DR is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -7.10% yearly.
EPS Next Y34.23%
EPS Next 2Y14.43%
EPS Next 3Y10.76%
EPS Next 5YN/A
Revenue Next Year-20.98%
Revenue Next 2Y-10.85%
Revenue Next 3Y-7.1%
Revenue Next 5YN/A

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
DR.CA Yearly Revenue VS EstimatesDR.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 100M 200M 300M 400M
DR.CA Yearly EPS VS EstimatesDR.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 0.5 1

9

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 9.44, which indicates a very decent valuation of DR.
92.86% of the companies in the same industry are more expensive than DR, based on the Price/Earnings ratio.
When comparing the Price/Earnings ratio of DR to the average of the S&P500 Index (26.61), we can say DR is valued rather cheaply.
A Price/Forward Earnings ratio of 9.14 indicates a reasonable valuation of DR.
Based on the Price/Forward Earnings ratio, DR is valued cheaply inside the industry as 100.00% of the companies are valued more expensively.
DR's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 24.01.
Industry RankSector Rank
PE 9.44
Fwd PE 9.14
DR.CA Price Earnings VS Forward Price EarningsDR.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, DR is valued cheaper than 100.00% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, DR is valued cheaply inside the industry as 92.86% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 4.15
EV/EBITDA 4.49
DR.CA Per share dataDR.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

DR's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
DR has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)0.28
PEG (5Y)N/A
EPS Next 2Y14.43%
EPS Next 3Y10.76%

5

5. Dividend

5.1 Amount

DR has a Yearly Dividend Yield of 2.35%. Purely for dividend investing, there may be better candidates out there.
Compared to an average industry Dividend Yield of 1.17, DR pays a better dividend. On top of this DR pays more dividend than 85.71% of the companies listed in the same industry.
DR's Dividend Yield is a higher than the S&P500 average which is at 1.87.
Industry RankSector Rank
Dividend Yield 2.35%

5.2 History

The dividend of DR decreases each year by -19.91%.
DR has paid a dividend for at least 10 years, which is a reliable track record.
DR has not decreased its dividend in the last 3 years.
Dividend Growth(5Y)-19.91%
Div Incr Years1
Div Non Decr Years4
DR.CA Yearly Dividends per shareDR.CA Yearly Dividends per shareYearly Dividends per share 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0.2 0.4 0.6 0.8 1

5.3 Sustainability

6.72% of the earnings are spent on dividend by DR. This is a low number and sustainable payout ratio.
DP6.72%
EPS Next 2Y14.43%
EPS Next 3Y10.76%
DR.CA Yearly Income VS Free CF VS DividendDR.CA Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M 60M
DR.CA Dividend Payout.DR.CA Dividend Payout, showing the Payout Ratio.DR.CA Dividend Payout.PayoutRetained Earnings

MEDICAL FACILITIES CORP

TSX:DR (12/22/2025, 7:00:00 PM)

15.48

+0.06 (+0.39%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)11-06 2025-11-06/bmo
Earnings (Next)03-11 2026-03-11
Inst Owners11.98%
Inst Owner ChangeN/A
Ins Owners0%
Ins Owner ChangeN/A
Market Cap279.41M
Revenue(TTM)257.36M
Net Income(TTM)81.33M
Analysts42.22
Price Target16.58 (7.11%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 2.35%
Yearly Dividend0.35
Dividend Growth(5Y)-19.91%
DP6.72%
Div Incr Years1
Div Non Decr Years4
Ex-Date12-31 2025-12-31 (0.09)
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.6%
Min EPS beat(2)-7.54%
Max EPS beat(2)6.33%
EPS beat(4)2
Avg EPS beat(4)3.38%
Min EPS beat(4)-24.98%
Max EPS beat(4)39.71%
EPS beat(8)3
Avg EPS beat(8)-25.78%
EPS beat(12)5
Avg EPS beat(12)32.86%
EPS beat(16)7
Avg EPS beat(16)-103.27%
Revenue beat(2)1
Avg Revenue beat(2)-1.3%
Min Revenue beat(2)-4.5%
Max Revenue beat(2)1.91%
Revenue beat(4)1
Avg Revenue beat(4)-6.39%
Min Revenue beat(4)-18.84%
Max Revenue beat(4)1.91%
Revenue beat(8)3
Avg Revenue beat(8)-3.49%
Revenue beat(12)4
Avg Revenue beat(12)-2.43%
Revenue beat(16)5
Avg Revenue beat(16)-2.23%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)15.63%
EPS NY rev (1m)1.24%
EPS NY rev (3m)1.24%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)1.91%
Revenue NY rev (1m)1.27%
Revenue NY rev (3m)1.27%
Valuation
Industry RankSector Rank
PE 9.44
Fwd PE 9.14
P/S 0.79
P/FCF 4.15
P/OCF 3.82
P/B 2.36
P/tB N/A
EV/EBITDA 4.49
EPS(TTM)1.64
EY10.59%
EPS(NY)1.69
Fwd EY10.95%
FCF(TTM)3.73
FCFY24.08%
OCF(TTM)4.05
OCFY26.16%
SpS19.63
BVpS6.57
TBVpS-0.86
PEG (NY)0.28
PEG (5Y)N/A
Graham Number15.57
Profitability
Industry RankSector Rank
ROA 30.18%
ROE 94.43%
ROCE 18.66%
ROIC 15.42%
ROICexc 19.71%
ROICexgc 46.81%
OM 15.59%
PM (TTM) 31.6%
GM 63.75%
FCFM 18.99%
ROA(3y)8.42%
ROA(5y)6.13%
ROE(3y)25.39%
ROE(5y)18.93%
ROIC(3y)16.37%
ROIC(5y)14.6%
ROICexc(3y)21.7%
ROICexc(5y)18.79%
ROICexgc(3y)53.59%
ROICexgc(5y)43.79%
ROCE(3y)19.81%
ROCE(5y)17.76%
ROICexgc growth 3Y35.06%
ROICexgc growth 5Y23.36%
ROICexc growth 3Y18.42%
ROICexc growth 5Y13.1%
OM growth 3Y-0.97%
OM growth 5Y-1.3%
PM growth 3Y78.64%
PM growth 5Y55.2%
GM growth 3Y-0.53%
GM growth 5Y-0.42%
F-Score6
Asset Turnover0.95
Health
Industry RankSector Rank
Debt/Equity 1.02
Debt/FCF 2.05
Debt/EBITDA 1.54
Cap/Depr 25.03%
Cap/Sales 1.64%
Interest Coverage 7.65
Cash Conversion 93.1%
Profit Quality 60.09%
Current Ratio 1.79
Quick Ratio 1.67
Altman-Z 1.35
F-Score6
WACC8.5%
ROIC/WACC1.81
Cap/Depr(3y)47.79%
Cap/Depr(5y)40.36%
Cap/Sales(3y)2.81%
Cap/Sales(5y)2.52%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)60.81%
EPS 3Y10.86%
EPS 5Y0%
EPS Q2Q%-23.33%
EPS Next Y34.23%
EPS Next 2Y14.43%
EPS Next 3Y10.76%
EPS Next 5YN/A
Revenue 1Y (TTM)-41.68%
Revenue growth 3Y-5.96%
Revenue growth 5Y-3.59%
Sales Q2Q%-20.29%
Revenue Next Year-20.98%
Revenue Next 2Y-10.85%
Revenue Next 3Y-7.1%
Revenue Next 5YN/A
EBIT growth 1Y-46.1%
EBIT growth 3Y-6.86%
EBIT growth 5Y-4.85%
EBIT Next Year4.4%
EBIT Next 3Y2.19%
EBIT Next 5YN/A
FCF growth 1Y-6.31%
FCF growth 3Y4.28%
FCF growth 5Y3.38%
OCF growth 1Y-24.65%
OCF growth 3Y3.26%
OCF growth 5Y1.55%

MEDICAL FACILITIES CORP / DR.CA FAQ

What is the fundamental rating for DR stock?

ChartMill assigns a fundamental rating of 7 / 10 to DR.CA.


What is the valuation status for DR stock?

ChartMill assigns a valuation rating of 9 / 10 to MEDICAL FACILITIES CORP (DR.CA). This can be considered as Undervalued.


Can you provide the profitability details for MEDICAL FACILITIES CORP?

MEDICAL FACILITIES CORP (DR.CA) has a profitability rating of 8 / 10.


Can you provide the PE and PB ratios for DR stock?

The Price/Earnings (PE) ratio for MEDICAL FACILITIES CORP (DR.CA) is 9.44 and the Price/Book (PB) ratio is 2.36.


Can you provide the dividend sustainability for DR stock?

The dividend rating of MEDICAL FACILITIES CORP (DR.CA) is 5 / 10 and the dividend payout ratio is 6.72%.